Disease · MONDO_0006684

brain edema

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. brain edema. Diseases, record MONDO_0006684. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006684

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: brain edema; Open Targets
Open Targets ID: MONDO_0006684; Open Targets
Other names: Brain oedema, Cerebral edema, Cerebral oedema, Swelling of brain, intracranial swelling, wet brain; Open Targets
Disease Ontology: DOID:4724; Disease Ontology
MeSH: D001929; MeSH
Highest stage of its drugs: Approval, for 2 of its 17 drugs, from DailyMed; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MANNITOL	CHEMBL689	Small molecule	Approval	DailyMed	6	2	2	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	7	7	2	Drugs and targets
GLYBURIDE	CHEMBL472	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ESMOLOL	CHEMBL768	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB	CHEMBL941	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TERAZOSIN	CHEMBL611	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
URAPIDIL	CHEMBL279229	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets20

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	2	Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Beta-2 adrenergic receptor	2	Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
ABCC8	Sulfonylurea receptor 1, Kir6.2	1	Sulfonylurea receptor 1, Kir6.2 blocker	Phase 3	https://conductscience.org/library/genes/6833	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
AGER	Advanced glycosylation end product-specific receptor	1	Advanced glycosylation end product-specific receptor antagonist	Phase 1	https://conductscience.org/library/genes/177	Drugs and targets
AVPR1A	Vasopressin V1a receptor	1	Vasopressin V1a receptor antagonist	Phase 2	https://conductscience.org/library/genes/552	Drugs and targets

1 to 10 of 20

See all 20 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02864953	Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction	Phase 3	535	2024-01-09	Brain Edema, Stroke, Acute	GLYBURIDE	Its record names the disease	ClinicalTrials.gov
NCT03000283	Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study	Phase 1	7	2020-04-17	Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke	CONIVAPTAN	Its record names the disease	ClinicalTrials.gov
NCT03276494	Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access	Phase 2	6	2019-07-09	Stroke, Intracranial Hypotension, Cerebral Edema	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02157103	A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma	Phase 2	3	2018-04-13	Glioblastoma	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03639922	Imatinib in Acute Ischaemic Stroke	Phase 3	1,260		Acute Ischaemic Stroke	IMATINIB	Its record names the disease	ClinicalTrials.gov
NCT03741530	Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage	Not applicable	220		Intracerebral Hemorrhage	GLYBURIDE	Its record names the disease	ClinicalTrials.gov
NCT06863571	Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke	Phase 3	68		Ischemic Stroke	ESMOLOL, PROPRANOLOL, TERAZOSIN, URAPIDIL	Its record names the disease	ClinicalTrials.gov
NCT03208413	The Therapeutic Effect of Thalidomide in RI	Phase 2	58		Radiation Injuries	THALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT06110429	Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients	Phase 3	52		Intra Cerebral Hypertension, Lactate Sodium Solution	SODIUM LACTATE	Its record names the disease	ClinicalTrials.gov
NCT03341676	Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)	Phase 1	10		High Altitude Cerebral Edema	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
BIIB093 vs Placebo: deaths from any cause	103 of 259	97 of 259	518	NCT02864953	Trial comparisons
BIIB093 vs Placebo: serious adverse events	199 of 259	177 of 259	518	NCT02864953	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39577921	DERIVED	1	PubMed
37449423	DERIVED	1	PubMed
36812346	DERIVED	1	PubMed
36177443	DERIVED	1	PubMed
33986719	DERIVED	1	PubMed
32253717	DERIVED	1	PubMed
31651350	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006684

GET https://conductscience.org/api/diseases/v1/MONDO_0006684/drugs

API reference For AI assistants